Tirzepatide
A Study to Evaluate ALN-2232 in Participants With Obesity
Eli Lilly · Phase 1/2 · Recruiting · Enrollment 156
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Part A: ALN-2232 | n/r | n/r | n/r | n/r | n/r |
| Part A: Placebo | n/r | n/r | n/r | n/r | n/r |
| Part B: ALN-2232 | n/r | n/r | n/r | n/r | n/r |
| Part B: Placebo | n/r | n/r | n/r | n/r | n/r |
| Part C: ALN-2232 | n/r | n/r | n/r | n/r | n/r |
| Part C: Placebo | n/r | n/r | n/r | n/r | n/r |
| Part C: Tirzepatide | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.